[HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs]

G Ital Nefrol. 2024 Jun 28;41(3):2024-vol3. doi: 10.69097/41-03-2024-03.
[Article in Italian]

Abstract

Roxadustat, recently approved, is a hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. This article reviews main features and possible effects by activation of pathway sequences HREs.

Keywords: EPO; Roxadustat; hypoxia-inducible factor; inflammation; oxidative stress.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anemia* / drug therapy
  • Anemia* / etiology
  • Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors
  • Basic Helix-Loop-Helix Transcription Factors / metabolism
  • Glycine / analogs & derivatives
  • Glycine / therapeutic use
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Isoquinolines / therapeutic use
  • Molecular Targeted Therapy
  • Prolyl-Hydroxylase Inhibitors / pharmacology
  • Prolyl-Hydroxylase Inhibitors / therapeutic use

Substances

  • roxadustat
  • Isoquinolines
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Glycine
  • HIF1A protein, human
  • Prolyl-Hydroxylase Inhibitors
  • Basic Helix-Loop-Helix Transcription Factors